Press

Algernon NeuroScience Doses First Subject in Phase 1 DMT Clinical Stroke Study

Jan 18 • 5 min read

Algernon Pharmaceuticals Inc. (CSE: AGN | FRANKFURT: AGW0 | OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to advise that its subsidiary, Algernon NeuroScience (AGN Neuro), has dosed the first subject in its Phase 1 clinical study of an intravenous formulation of AP-188 (“N,N-Dimethyltryptamine” or “DMT”) in the Netherlands. The trial is…

Israel-Based Clearmind Announces Additional Positive Results from the Third Part of its Pre-Clinical Study for Cocaine Addiction Treatment

Jan 18 • 3 min read

Clearmind Medicine Inc. (Nasdaq, CSE: CMND | FSE: CWY), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced additional positive pre-clinical results in its ongoing series of research studies conducted to illuminate the tremendous potential of MEAI and its effect on substance-use-disorder (SUD). The…

FSD Pharma Inc. Board Authorized Share Repurchase Program

Jan 16 • 2 min read

FSD Pharma (NASDAQ: HUGE | CSE: HUGE | FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has announced a share repurchase program. The company’s board of directors approved the repurchase under a normal course issuer bid; the bid is comprised of…

Mindbloom partners with This is Jane Project to offer affordable at-home ketamine therapy to trauma survivors

Jan 16 • 3 min read

Mindbloom, the world’s largest provider of ketamine therapy, announced Monday the launch of their partnership with This is Jane Project, a nonprofit organization that supports and builds community for women and non-binary survivors of trauma. Through this partnership, This is Jane Project’s members will be able to access Mindbloom’s at-home ketamine therapy programs at a substantial…

atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917

Jan 16 • 4 min read

Today, atai Life Sciences N.V. (Nasdaq: ATAI) a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its subsidiary GABA Therapeutics, announced final positive results from a Phase 1 clinical trial of GRX-917 that were previously announced as preliminary results during atai’s R&D day. The randomized, double-blind, placebo-controlled trial was designed…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420